SYS6020 / CSPC Pharma - LARVOL DELTA

SYS6020-004: A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Myasthenia Gravis

A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

CAR T-Cell Therapy • New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

New P1 trial • CNS Disorders • Myasthenia Gravis

VOLUNTARY ANNOUNCEMENT FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020)OBTAINS CLINICAL TRIAL APPROVAL FOR NEW INDICATION (CSPC Press Release) - "The board of directors (the 'Board') of CSPC Pharmaceutical Group Limited...is pleased to announce that the first mRNA-Lipid Nanoparticles (LNP)-based Chimeric Antigen Receptor (CAR)-T Cell Injection (SYS6020) targeting B-cell maturation antigen (BCMA) (the 'Product') developed by the Group has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials for the indication of systemic lupus erythematosus (SLE) in China."

New trial • Systemic Lupus Erythematosus

Shijiazhuang Pharmaceutical Group announced that the first mRNA-LNP-based CAR-T cell injection (SYS6020) has been approved for clinical trials. [Google translation] (Daily Economic News - NBD) - "On June 25, Shijiazhuang Pharmaceutical Group announced that the first mRNA-LNP-based CAR-T cell injection (SYS6020) was approved for clinical trials."

New trial • Oncology

Study of SYS6020 in BCMA-positive Multiple Myeloma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Wuhan Union Hospital, China

CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology